(A) Following FGFR4 and Klotho (KLB) bind to FGF19, activated FGFR4 forms homo- or heterodimer and subsequently activates multiple downstream signaling pathways including Ras-Raf- MAPK, PI3K-AKT, EMT, and JAK/STAT. (B) Expression of FGFR4 in various The Cancer Genome Atlas (TCGA) cancer types by http://ualcan.path.uab.edu/cgi-bin/Pan-cancer.pl?genenam=FGFR4, X axis represents 33 TCGA different cancer types (ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangio carcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma). Y axis represents log2 (TPM + 1) transformed expression data for plotting (TPM, transcripts per million).